A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injections of Sirolimus [Rapamycin] in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy.

Trial Profile

A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injections of Sirolimus [Rapamycin] in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2013

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Oct 2009 Enrollment of 131 patients has been completed, as reported in a MacuSight media release.
    • 05 Jun 2009 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top